Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAVAnc80-hOTOF gene therapy trial for otoferlin-related sensorineural hearing loss
jRCT2053260205Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2027
- Modality
- Gene Therapies
01
Overview
Open-label trial of AK-OTOF in sensorineural hearing loss (SNHL) and autosomal recessive nonsyndromic deafness 9 (DFNB9) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Frequency of adverse events, ABR threshold and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
AK-OTOF
03
Conditions
sensorineural hearing loss (SNHL)autosomal recessive nonsyndromic deafness 9 (DFNB9)
Beyond the preview
Go deeper on jRCT2053260205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053260205.